Bros. Advisors Lp Baker Sells 256,035 Shares of Genomic Health, Inc. (GHDX) Stock

Genomic Health, Inc. (NASDAQ:GHDX) Director Bros. Advisors Lp Baker sold 256,035 shares of Genomic Health stock in a transaction that occurred on Friday, November 30th. The stock was sold at an average price of $78.95, for a total transaction of $20,213,963.25. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Bros. Advisors Lp Baker also recently made the following trade(s):

  • On Monday, December 3rd, Bros. Advisors Lp Baker sold 202,134 shares of Genomic Health stock. The shares were sold at an average price of $78.49, for a total transaction of $15,865,497.66.
  • On Monday, November 26th, Bros. Advisors Lp Baker sold 39,675 shares of Genomic Health stock. The shares were sold at an average price of $74.28, for a total transaction of $2,947,059.00.
  • On Wednesday, November 28th, Bros. Advisors Lp Baker sold 250,392 shares of Genomic Health stock. The shares were sold at an average price of $75.61, for a total transaction of $18,932,139.12.
  • On Friday, November 16th, Bros. Advisors Lp Baker sold 87,395 shares of Genomic Health stock. The shares were sold at an average price of $76.65, for a total transaction of $6,698,826.75.
  • On Friday, November 9th, Bros. Advisors Lp Baker sold 169,344 shares of Genomic Health stock. The shares were sold at an average price of $82.51, for a total transaction of $13,972,573.44.
  • On Tuesday, November 13th, Bros. Advisors Lp Baker sold 204,300 shares of Genomic Health stock. The shares were sold at an average price of $79.33, for a total transaction of $16,207,119.00.

Shares of Genomic Health stock traded down $1.05 on Monday, hitting $78.00. 738,600 shares of the company traded hands, compared to its average volume of 292,141. Genomic Health, Inc. has a 12-month low of $26.54 and a 12-month high of $92.18. The stock has a market cap of $2.86 billion, a P/E ratio of 7,800.00 and a beta of 0.39.

Genomic Health (NASDAQ:GHDX) last issued its quarterly earnings data on Tuesday, November 6th. The medical research company reported $0.35 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.07 by $0.28. The firm had revenue of $101.30 million during the quarter, compared to analysts’ expectations of $94.27 million. Genomic Health had a net margin of 4.95% and a return on equity of 14.05%. Genomic Health’s revenue for the quarter was up 23.2% on a year-over-year basis. During the same period in the prior year, the company posted ($0.06) earnings per share. On average, research analysts anticipate that Genomic Health, Inc. will post 1.06 earnings per share for the current year.

GHDX has been the topic of several research analyst reports. Raymond James initiated coverage on shares of Genomic Health in a report on Tuesday, October 23rd. They set a “market perform” rating on the stock. Zacks Investment Research restated a “hold” rating on shares of Genomic Health in a report on Tuesday, November 13th. BidaskClub upgraded shares of Genomic Health from a “buy” rating to a “strong-buy” rating in a report on Tuesday, October 30th. Canaccord Genuity restated a “buy” rating and set a $82.00 price target (up from $70.00) on shares of Genomic Health in a report on Wednesday, November 7th. Finally, Cowen restated a “hold” rating and set a $50.00 price target on shares of Genomic Health in a report on Monday, August 6th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating, one has issued a buy rating and two have given a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $48.33.

A number of large investors have recently modified their holdings of GHDX. Globeflex Capital L P bought a new stake in Genomic Health in the second quarter worth $116,000. Sun Life Financial INC bought a new stake in Genomic Health in the second quarter worth $122,000. SG Americas Securities LLC bought a new stake in Genomic Health in the second quarter worth $162,000. Pacer Advisors Inc. bought a new stake in Genomic Health in the third quarter worth $171,000. Finally, Trexquant Investment LP bought a new stake in Genomic Health in the third quarter worth $202,000. Hedge funds and other institutional investors own 89.21% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Bros. Advisors Lp Baker Sells 256,035 Shares of Genomic Health, Inc. (GHDX) Stock” was first reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at https://www.com-unik.info/2018/12/03/bros-advisors-lp-baker-sells-256035-shares-of-genomic-health-inc-ghdx-stock.html.

About Genomic Health

Genomic Health, Inc, a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.

Read More: What is insider trading?

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit